ERBB2 and breast cancer: Despite the recognised role of immune cells in HER2+ BC, the composition, localisation and functional orientation of immune cells within the tumour microenvironment (jointly referred to as immune contexture), as well as the dynamics of TILs during and after anti-HER2 treatment, are largely unknown.